(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 9.97% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Pulmonx's revenue in 2025 is $91,664,000.On average, 8 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,815,680,621, with the lowest LUNG revenue forecast at $3,637,988,399, and the highest LUNG revenue forecast at $3,974,522,949. On average, 8 Wall Street analysts forecast LUNG's revenue for 2026 to be $4,234,832,981, with the lowest LUNG revenue forecast at $3,983,184,826, and the highest LUNG revenue forecast at $4,512,837,990.
In 2027, LUNG is forecast to generate $5,113,394,805 in revenue, with the lowest revenue forecast at $4,470,766,015 and the highest revenue forecast at $6,547,141,707.